A Form 4 filed with the SEC on September 16, 2026 discloses that Albert Bourla, Chairman and CEO of Pfizer Inc. (NYSE:PFE), acquired 22 Phantom Stock Units under the company's Nonfunded Deferred Compensation and Supplemental Savings Plan, with a transaction date of September 15, 2026.

Key Highlights

  • Reporting person: Albert Bourla, identified as Director and Chairman and CEO of Pfizer Inc.
  • Security acquired: 22 Phantom Stock Units (SSP), each representing one phantom share of common stock, at a price of $27.55.
  • Transaction code: A (acquisition), dated September 15, 2026.
  • Post-transaction holdings: Bourla beneficially owns 783,985 Phantom Stock Units following the reported transaction, held directly.
  • Settlement terms: According to the filing, the units "are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time."
  • Plan source: Units were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan.

Bourla's Phantom Stock Unit Acquisition Under Pfizer Deferred Compensation Plan

According to the filing, Albert Bourla acquired 22 Phantom Stock Units under Table II (Derivative Securities) on September 15, 2026. The filing identifies these as "Phantom Stock Units SSP," with each unit representing one phantom share of Pfizer common stock. The acquisition price listed is $27.55 per unit. The transaction code is recorded as "A," indicating an acquisition, and the units are held directly by the reporting person.

The filing explains that these units were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan. Per the filing's explanation of responses, the units "are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time." No expiration date or exercisable date is specified in the filing for these units. Following this transaction, Bourla's total beneficial ownership of Phantom Stock Units stands at 783,985, held directly.

The Form 4 was signed by Shanice A. Reid, by power of attorney for Albert Bourla, on September 16, 2026. No non-derivative securities transactions were reported in Table I of this filing. The filing does not indicate that the transaction was made pursuant to a Rule 10b5-1(c) plan.

What Was Disclosed

Pfizer Chairman and CEO Albert Bourla acquired 22 Phantom Stock Units at $27.55 each on September 15, 2026, under a company deferred compensation plan, bringing his total direct beneficial ownership of such units to 783,985, according to a Form 4 filed on September 16, 2026.